The KRAS G12C mutation, unlike BRAF, HER2, and general RAS status, may frequently go unnoticed.
Look deeper to find the 4% of patients with mCRC with the KRAS G12C mutation, a biomarker that may be associated with a worse prognosis.1,2
Ensure biomarker test results are retrievable to help inform clinical decisions
BRAF, proto-oncogene B-Raf; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; mCRC, metastatic colorectal cancer; RAS, rat sarcoma.
References: 1. Peeters M, et al. Eur J Cancer. 2015;51:1704-1713. 2. Fakih M, et al. Oncologist. 2022;27:663-674.